Induction of fetal hemoglobin in sickle cell patients by hydroxyurea: the N.I.H. experience.
Rodgers
G P
GP
Laboratory of Chemical Biology, NIDDK, Bethesda, Maryland 20892.
Dover
G J
GJ
Noguchi
C T
CT
Schechter
A N
AN
Nienhuis
A W
AW
D000328:Adult; D000755:Anemia, Sickle Cell / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004906:Erythrocyte Count / Q000187:drug effects; D005260:Female; D005319:Fetal Hemoglobin / Q000096:biosynthesis* / Q000187:drug effects; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D009316:National Institutes of Health (U.S.); D012156:Reticulocytes / Q000187:drug effects; D014481:United States
D005319:Fetal Hemoglobin; D006918:Hydroxyurea